美国微创肺叶切除术的应用日益增多
该研究基于美国国家癌症数据库2010至2017年数据,评估I期和II期非小细胞肺癌(NSCLC)微创肺叶切除术的趋势与结局。结果显示微创手术使用显著增加,中转开胸率显著下降,至2017年微创已成为I期和II期NSCLC的主要术式。
要点
- 2010至2017年,I期NSCLC微创肺叶切除术使用增加(aOR 4.52;95%CI 3.95-5.18;P<.001)。
- 2015年I期NSCLC微创肺叶切除术占比52.2%(n=5647),首次超过开胸47.8%(n=5164)。
- 2017年II期NSCLC微创肺叶切除术占比54.7%(n=1620),超过开胸45.3%(n=1342)。
核心结论
- 2010至2017年美国I期和II期NSCLC微创肺叶切除术使用显著增加,中转开胸率显著下降,至2017年微创已成为I期和II期NSCLC的主要术式。
研究设计与样本
- 基于美国国家癌症数据库2010至2017年临床I期和II期NSCLC开胸与微创肺叶切除术的使用及结局,采用多变量logistic回归和倾向性评分匹配进行分析。
主要发现
- 2010至2017年,I期NSCLC微创肺叶切除术使用增加(多变量校正比值比aOR 4.52;95%CI 3.95-5.18;P<.001),II期NSCLC亦增加(aOR 4.38;95%CI 3.38-5.68;P<.001)。
- 2015年I期NSCLC微创肺叶切除术占比52.2%(n=5647),开胸占比47.8%(n=5164),微创首次超过开胸。
- 2017年II期NSCLC微创肺叶切除术占比54.7%(n=1620),开胸占比45.3%(n=1342),微创超过开胸。
- 2010至2017年,I期NSCLC微创中转开胸率从19.6%(n=466)降至7.2%(n=521;aOR 0.32;95%CI 0.23-0.43;P<.001)。
- 2010至2017年,II期NSCLC微创中转开胸率从20%(n=114)降至11.5%(n=186;aOR 0.39;95%CI 0.21-0.72;P=.002)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The objective of this study is to evaluate the trends of and outcomes associated with the use of minimally invasive lobectomy for stage I and II non-small cell lung cancer (NSCLC) in the United States. METHODS: The use of and outcomes associated with open and minimally invasive lobectomy for clinical stage I and stage II NSCLC from 2010 to 2017 in the National Cancer Database were assessed by multivariable logistic regression and propensity score matching. RESULTS: From 2010 to 2017, use of minimally invasive lobectomies increased for stage I NSCLC (multivariable-adjusted odds ratio [aOR] 4.52; 95% CI, 3.95-5.18; P < .001) and stage II NSCLC (aOR 4.38; 95% CI, 3.38-5.68; P < .001). In 2015, for the first time, more lobectomies for stage I NSCLC were performed by minimally invasive techniques (52.2%, n = 5647) than by thoracotomy (47.8%, n = 5164); and in 2017, more lobectomies for stage II NSCLC were performed by minimally invasive techniques (54.7%, n = 1620) than by thoracotomy (45.3%, n = 1,342). From 2010 to 2017, the conversion rates from minimally invasive to open lobectomy for stage I NSCLC decreased from 19.6% (n = 466) to 7.2% (n = 521; aOR 0.32; 95% CI, 0.23-0.43; P < .001). Similarly, from 2010 to 2017, the conversion rates from minimally invasive to open lobectomy for stage II NSCLC decreased from 20% (n = 114) to 11.5% (n = 186; aOR 0.39; 95% CI, 0.21-0.72; P = .002). CONCLUSIONS: In the United States, for stage I and stage II NSCLC from 2010 to 2017, the use of minimally invasive lobectomy significantly increased while the conversion rate significantly decreased. By 2017, the minimally invasive approach had become the predominant approach for both stage I and stage II NSCLC.
引用
- Potter AL, Spasojevic A, Raman V, et al. The Increasing Adoption of Minimally Invasive Lobectomy in the United States. Ann Thorac Surg. 2022. PMID: 36223806. doi:10.1016/j.athoracsur.2022.09.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。